Trial of NanoPac Intratumoral Injection in Lung Cancer

Inclusion Criteria: * Signed informed consent; * Age ≥18 years and able to tolerate the EBUS-TBNI procedure; * Histologically/cytologically confirmed lung cancer. Eligible subjects may include, for example: primary or recurrent non-resectable disease, locally advanced stages II and III with nodal disease, stage IV advanced disease; * At least one lesion documented via imaging (within 4 weeks of Screening) which can be accessed using EBUS-TBNI; * Subject is not a candidate for surgery; * Has received or plans to receive SOC chemotherapy; adequate hematologic recovery must be confirmed according to the institution's SOC; * Performance Status (ECOG) 0-2 at study entry; * Life expectancy of at least 6 months; * Adequate marrow, liver, and renal function at study entry; * ANC ≥ 1.5 x 109/L; * Hemoglobin ≥ 9.0 grams/dL; * Platelets ≥ 75 x 109/L; * Total bilirubin ≤ 1.5x institutional ULN; * AST/ ALT ≤ 2.5x institutional ULN; * Creatinine ≤ 1.5x institutional ULN; * Appropriate steps taken to minimize or avoid the potential for pregnancy for subjects of child-bearing potential.\* Exclusion Criteria: * Significant cardiac disease (Class III or IV per New York Heart Association guidelines); * Active bacterial, viral, or fungal infections (including active AIDS, hepatitis B or hepatitis C); * Symptomatic central nervous system (CNS) metastasis which are neurologically unstable, or CNS disease requiring increase in steroid dose (treated metastatic disease and stable steroid use are not excluded) * Known hypersensitivity to study agent; * Pregnant or breastfeeding women.